Helsinn's anamorelin improves lean body mass in anorexia-cachexia according to Phase III data

30 October 2014
helsinn-big

Family-owned Swiss cancer specialist Helsinn has reported positive results from a Phase III study of anamorelin in anorexia-cachexia syndrome.

Anamorelin is an investigational once-daily ghrelin receptor agonist and has delivered significant improvements in lean body mass, one of two primary endpoints, in non-small cell lung cancer patients. Anorexia-cachexia affects a majority of advanced cancer patients, and at present existing treatment approaches are limited.

The results underscore the potential for treatment with anamorelin to support the care of patients with CACS, a poorly-understood and debilitating condition that affects a majority of advanced cancer patients but for which existing treatment approaches are limited.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical